Custom iScale Oligos™

iScale Oligos DNA and siRNA are milligram and gram quantities of custom DNA and siRNA oligonucleotides manufactured to meet specialized needs.

DNA

Milligram and gram quantities of Custom DNA Oligos are for in vivo, high-throughput, and commercial projects (life science research tools, molecular diagnostics, and laboratory developed tests). For iScale quantities of NGS adapters, please see our Next-Gen Sequencing Oligos product

Product Benefits

  • Amounts available to meet your experimental and commercial needs
  • Consultation with our scientific team to set specifications for your application
  • State-of-the-art analytical laboratory, ensuring a high-quality product

Product Features

For anything marked as ‘Inquire’ below or If you have needs that are different from the other general specifications presented, please send a request to dnaoligos@milliporesigma.com.

iScale Oligos DNA Specifications

Useful Applications

  • Antisense
  • Binding studies
  • High-throughput PCR/qPCR
  • Sanger Sequencing & NGS (non-adapters)
  • X-ray crystallographic structure determination
  • Immunostimulatory assays
  • Microarray production

Quality Assurance

At the foundation of our manufacturing processes is a robust Quality Management System (QMS), which drives compliance to our following Quality Registrations:

  • ISO 9001:2015 for manufacturing research-grade oligonucleotides
  • ISO 13485:2016 for manufacturing diagnostic-grade oligonucleotides
  • ISO 14001:2015 for effective environmental management

This quality culture is integrated into all aspects of our business. Key components of our QMS include:

  • Certificates of analysis
  • Document control
  • Change notification
  • Vendor management
  • Business agreements
  • Corrective and preventive actions

Each component drives quality assurance, and for verification, we routinely host rigorous registrar, internal, and customer audits.

siRNA

Milligram and gram quantities of MISSION in-vivo-quality siRNA are superior for RNAi research in animals. We also manufacture other types of RNA, including miRNA and single-stranded RNA.

Product Benefits

  • Suitable for in vivo applications, including target validation and pre-clinical testing
  • Available for MISSION Predesigned siRNA or your custom siRNA sequences
  • Appropriate for direct delivery or as an essential component of your formulation strategy

Product Features

For anything marked as ‘Inquire’ below or If you have needs that are different from the other general specifications presented, please send a request to sirnarequest@milliporesigma.com.

iScale Oligos siRNA Specifications

*Depending on manufacturing site, PAGE may be used to assess siRNA duplexes.

Demonstrated Use In Vivo

We teamed up with Bioo Scientific (now PerkinElmer) to validate our MISSION in-vivo-quality siRNA (see article in Drug Discovery & Development—Aug 1, 2008).

In these experiments, H1155luc cells were injected into NOD/SCID mice. Tumors formed and were injected with luciferase-specific siRNA or non-targeting in-vivo-quality siRNA formulated in MaxSuppressor™ In Vivo RNA-LANCEr II. After 24 hours, D-luciferin solution was injected, and the animals were imaged using the NightOWL II LB 983 instrument from Berthold Technologies. Animals treated with luciferase-specific siRNA showed significant reduction of luciferase activity while non-targeting siRNA-treated animals were positive for luminescence (Figure 1). These data demonstrate the effectiveness of in-vivo-quality siRNA formulated in MaxSuppressor™ In Vivo RNA-LANCEr II in vivo delivery agent.

Luciferase-specific siRNA treated animal on the left; non-targeting siRNA treated animal on the right

Figure 1.Luciferase-specific siRNA treated animal on the left; non-targeting siRNA treated animal on the right

At 72 hours post-injection, the tumors were removed, and the protein was extracted and normalized using a Bradford assay. Luciferase concentrations were assayed using a Luciferase ELISA. Protein reduction is represented relative to a non-targeting RNAi agent treated animal. Luciferase activity was reduced by two-fold in the tumors (Figure 2).

Each replicate is a different mouse

Figure 2.Each replicate is a different mouse

If additional help is needed, please consult our technical services group at oligotechserv@merckgroup.com.

MISSION is a trademark of Merck KGaA, Darmstadt, Germany and/or its affiliates. Label License.

Loading

References

1.
Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, et al. Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers. PLoS ONE. 6(7):e21121. http://dx.doi.org/10.1371/journal.pone.0021121
2.
Beghin A, Belin S, Hage-Sleiman R, Brunet Manquat S, Goddard S, Tabone E, Jordheim LP, Treilleux I, Poupon M, Diaz J, et al. Correction: ADP Ribosylation Factor Like 2 (Arl2) Regulates Breast Tumor Aggressivity in Immunodeficient Mice. PLoS ONE. 4(11): http://dx.doi.org/10.1371/annotation/b0d43779-c9aa-44fe-a46d-71d7d2bc4a6a
3.
Ramachandran V, Arumugam T, Langley R, Hwang RF, Vivas-Mejia P, Sood AK, Lopez-Berestein G, Logsdon CD. The ADMR Receptor Mediates the Effects of Adrenomedullin on Pancreatic Cancer Cells and on Cells of the Tumor Microenvironment. PLoS ONE. 4(10):e7502. http://dx.doi.org/10.1371/journal.pone.0007502
4.
Brahmamdam P, Watanabe E, Unsinger J, Chang KC, Schierding W, Hoekzema AS, Zhou TT, McDonough JS, Holemon H, Heidel JD, et al. 2009. TARGETED DELIVERY OF siRNA TO CELL DEATH PROTEINS IN SEPSIS. 32(2):131-139. http://dx.doi.org/10.1097/shk.0b013e318194bcee
5.
Fitamant J, Guenebeaud C, Coissieux M, Guix C, Treilleux I, Scoazec J, Bachelot T, Bernet A, Mehlen P. 2008. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proceedings of the National Academy of Sciences. 105(12):4850-4855. http://dx.doi.org/10.1073/pnas.0709810105
6.
Watabe M, Aoyama K, Nakaki T. 2008. A Dominant Role of GTRAP3-18 in Neuronal Glutathione Synthesis. Journal of Neuroscience. 28(38):9404-9413. http://dx.doi.org/10.1523/jneurosci.3351-08.2008

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.